A phase 3 trial of GLPG CAR T-cell therapy in advanced solid tumours, run by Lakefront Biotherapeutics NV, now recruiting.
Long-term Follow-up of Participants Treated With Galapagos Chimeric Antigen Receptor (CAR) T-cell Therapies is a phase 3 interventional study registered as NCT06652633 by Lakefront Biotherapeutics NV, with 546 participants planned, started 2024-09-09 and due to reach its primary completion in 2039-07. Interventions recorded: GLPG CAR T-cell therapy.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.